Announcements Trials
Browse Landscape

Phase

Phase 2 92Phase 1 21Phase 3 18Phase 1/2 15Phase NA 4Phase EARLY_PHASE1 3Phase 2/3 2Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Albumin-Bound Paclitaxel × Breast × Clear all
NCT01881230 2019-02-21

tnAcity

Celgene

Phase 2/3 Completed
191 enrolled 22 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01647672 2012-07-25

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Tianjin Medical University

Phase 2/3 Unknown
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡